Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schiff Nutrition rides private label growth

This article was originally published in The Tan Sheet

Executive Summary

The nutritional company's net sales rose 7.9 percent to 49.9 million on the strength of private label business in the fiscal third quarter (ended Feb. 28), though branded business hampered net sales in the period, the Salt Lake City-based firm reports March 17. Though Schiff's Move Free brand sales fell in the mid-single digits, MegaRed Krill Oil performed well, due in part to increased marketing, Schiff President and CEO Bruce Wood says. However, the National Advertising Division told Schiff to modify misleading MegaRed ad claims (1"The Tan Sheet" March 9, 2009, p. 10). Net earnings for the quarter were $3.6 million, compared to $4 million in the same period last year, negatively impacted by a compensation charge related to a special dividend. Schiff will continue supporting Move Free and MegaRed products and will "continue our efforts to explore other branded and private label organic growth opportunities as well as potential acquisition opportunities," Wood says

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts